The Alliance is an experienced multi-institutional cancer clinical trials group that has been reorganized in response to the Institute of Medicine (lOM) consensus report and NCI directives for cooperative group reorganization. Alliance provides a comprehensive and highly efficient clinical trials infrastructure, access to experienced collaborators across all disciplines of oncology clinical trials research, and a diverse portfolio f trials for patients with breast, gastrointestinal, genitourinary, respiratory, central nervous systm, hematological malignancies, and selected rare tumors. Particular strengths of the Alliance include the long-standing tradition of collaborative research of the legacy members, including many who have participated in cooperative group research since its inception in 1955. The Mission of the Alliance for Clinical Trials in Oncology is to reduce the impact of cancer by: - Conducting high quality multidisciplinary cancer control, prevention, and treatment trials that engage a comprehensive research network; - Furthering our understanding of the biological basis of the cancer process and its treatment; from discovery, to validation, to clinical practice;- Providing a scientific and operational infrastructure for innovative clinical and translational research in the academic and community settings.

Public Health Relevance

To reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA180821-02S2
Application #
9132519
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-17
Project End
2019-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
2
Fiscal Year
2015
Total Cost
$810,357
Indirect Cost
$63,517
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Neuman, Heather B; Schumacher, Jessica R; Francescatti, Amanda B et al. (2018) Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01). J Clin Oncol 36:975-980
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382
Walter, Roland B; Michaelis, Laura C; Othus, Megan et al. (2018) Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol 93:E49-E52
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227
Roboz, Gail J; Mandrekar, Sumithra J; Desai, Pinkal et al. (2018) Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv 2:3608-3617

Showing the most recent 10 out of 325 publications